PND20 The Cost-Effectiveness of Fremanezumab in Patients With Migraine and Previous Inadequate Response to OnabotulinumtoxinA From a UK Healthcare System Perspective
Abstract
Authors
A. Skroumpelos M. Freddi H. Akcicek J.M. Cohen M.T. Driessen